Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 1/2 1

Status

Active not recruiting 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

NET 5Endocrine 5Gastrointestinal 2Sarcoma 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × amino-acid, glucose, and electrolyte solution × Clear all
NCT06441331 2026-05-01

KinLET

ITM Solucin GmbH

Phase 1 Recruiting
20 enrolled
CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05475210 2024-03-13

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Molecular Targeting Technologies, Inc.

Phase 1 Unknown
9 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡